Phase 3Status unknown
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd (Industry)
- Enrolment
- 510 planned
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Degludec/liraglutide Injection; XULTOPHY®
- Ages
- adults, older adults
- Registry
- NCT06559722
Full record on ClinicalTrials.gov
From the registry
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.
Primary outcomes
- Change from baseline in HbA1c after 26 weeks of treatment
History
Study completion
Primary completion
Registered
Started